Antidepressants & Pregnancy: Risks of Stopping & Impact on Birth Outcomes

The decision of whether to continue or discontinue antidepressant medication during pregnancy is a complex one, fraught with potential risks and benefits for both mother and child. Recent data and ongoing research continue to refine our understanding of these risks, highlighting the importance of individualized treatment plans and open communication between patients and their healthcare providers.

The Risks of Untreated Maternal Depression

Maternal depression during pregnancy is not simply a matter of the mother’s well-being; it can have tangible consequences for the developing fetus and the course of the pregnancy. Studies have shown a correlation between untreated depression in pregnant women and increased rates of preterm birth. Untreated depression can also lead to an increased risk of substance use during pregnancy, compounding the potential harms. The decision to expose a fetus to antidepressant medication, must be carefully weighed against these risks.

Navigating Antidepressant Use During Pregnancy

For many years, concerns existed regarding potential birth defects associated with antidepressant use during pregnancy. However, current medical consensus, based on available evidence, does not support a definitive link between antidepressants and an increased risk of major birth defects. Nevertheless, the possibility of effects on the baby remains, necessitating careful consideration.

One area of ongoing scrutiny is neonatal withdrawal syndrome. Babies born to mothers who have been taking antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), may experience temporary withdrawal symptoms after birth. These symptoms can vary in severity but may include irritability, tremors, and feeding difficulties. While generally not life-threatening, these symptoms require monitoring and supportive care.

Another concern, though rare, is primary pulmonary hypertension of the newborn (PPHN), a serious condition affecting the lungs. Early studies suggested a possible association between SSRI use and PPHN, but the evidence remains controversial and requires further investigation.

The Consequences of Discontinuation

Recent research emphasizes the potential dangers of *stopping* antidepressant medication during pregnancy. A significant proportion of women discontinue their prescriptions during pregnancy, often driven by concerns about fetal safety or a desire to avoid medication. However, data suggests that doing so can significantly increase the risk of a mental health crisis for the mother. February 11, 2026, the New York Times reported on research showing that stopping antidepressants can be a health risk.

A study highlighted by U.S. News & World Report found that mental health risk more than doubled for women who quit antidepressants during pregnancy. Statnews.com reported that discontinuing antidepressants can lead to relapse of depression, potentially requiring more intensive interventions during and after pregnancy. Dr. Kelly B. Zafman, MD, MSCR, emphasized the risks associated with stopping medication, noting the potential for destabilization of a woman’s mental health during a vulnerable period.

Potential Benefits: A New Perspective

Interestingly, emerging research suggests a potential protective effect of antidepressants against preterm birth. Neuroscience News reported on findings indicating that antidepressants may safeguard against some of the risks associated with preterm delivery. While the mechanisms underlying this potential benefit are not yet fully understood, it adds another layer of complexity to the decision-making process.

Individualized Treatment is Key

Given the complexities and evolving understanding of antidepressant use during pregnancy, a one-size-fits-all approach is inappropriate. Treatment recommendations must be individualized, taking into account the patient’s history, the severity of her depression, the specific antidepressant she is taking, and her personal preferences.

A thorough discussion between the patient and her healthcare provider is crucial. This discussion should cover the potential risks and benefits of both continuing and discontinuing medication, as well as alternative treatment options such as psychotherapy. The goal is to develop a treatment plan that optimizes the mother’s mental health while minimizing potential risks to the fetus.

The decision is not simply about weighing risks; it’s about recognizing that untreated maternal depression carries its own set of risks, and that, for many women, antidepressants are a vital component of maintaining their well-being during pregnancy. Continued research and open communication will be essential to refining our understanding and providing the best possible care for pregnant women and their babies.